Cargando…

AB002. AUA guideline: update on Peyronie’s disease

Peyronie’s disease (PD) is the most common cause of acquired deformity of the penis and is characterized by the development of fibrotic, collagen-containing plaques, and some time penile ossification within the tunica albuginea (TA) resulting in penile deformity, pain, and erectile dysfunction (ED)....

Descripción completa

Detalles Bibliográficos
Autor principal: Lue, Tom F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186692/
http://dx.doi.org/10.21037/tau.2018.AB002
_version_ 1783362881638629376
author Lue, Tom F.
author_facet Lue, Tom F.
author_sort Lue, Tom F.
collection PubMed
description Peyronie’s disease (PD) is the most common cause of acquired deformity of the penis and is characterized by the development of fibrotic, collagen-containing plaques, and some time penile ossification within the tunica albuginea (TA) resulting in penile deformity, pain, and erectile dysfunction (ED). Currently, the prevalence of this disease has been reported to be between 3.2% and 8.9%. PD progresses in two phases: an acute phase that can last for up to one year, followed by a chronic phase. Formation of the plaque, the penile curvature, and the pain develop during the acute phase and the chronic phase is characterized by the stabilization of the curvature, decrease in penile pain, penile calcification or ossification, and development of ED. The AUA Guidelines Panel conducted a systematic review of the literature using the PubMed(®), EMBASE(®) and Cochrane databases to identify peer-reviewed publications relevant to the diagnosis and treatment of PD. A copy of the 2015 guidelines is attached. The most relevant recommendations are listed below: (I) clinicians should not offer oral therapy with vitamin E, tamoxifen, procarbazine, omega-3 fatty acids, or a combination of vitamin E with L-carnitine. [Moderate recommendation; evidence strength grade B (vitamin E)/B (omega-3 fatty acids)/B (vitamin E propionyl-lcarnitine)/C (tamoxifen)/C (procarbazine)]. (II) Clinicians may administer intralesional collagenase clostridium histolyticum in combination with modeling by the clinician and by the patient for the reduction of penile curvature in patients with stable PD, penile curvature >30. (III) Clinicians should counsel patients with PD prior to beginning treatment with intralesional collagenase regarding potential occurrence of adverse events, including penile ecchymosis, swelling, pain. (IV) Clinicians may offer tunical plication surgery to patients whose rigidity is adequate for coitus (with or without pharmacotherapy and/or vacuum device therapy) to improve penile curvature. (Moderate recommendation; evidence strength grade C).
format Online
Article
Text
id pubmed-6186692
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-61866922018-10-26 AB002. AUA guideline: update on Peyronie’s disease Lue, Tom F. Transl Androl Urol Plenary Session Peyronie’s disease (PD) is the most common cause of acquired deformity of the penis and is characterized by the development of fibrotic, collagen-containing plaques, and some time penile ossification within the tunica albuginea (TA) resulting in penile deformity, pain, and erectile dysfunction (ED). Currently, the prevalence of this disease has been reported to be between 3.2% and 8.9%. PD progresses in two phases: an acute phase that can last for up to one year, followed by a chronic phase. Formation of the plaque, the penile curvature, and the pain develop during the acute phase and the chronic phase is characterized by the stabilization of the curvature, decrease in penile pain, penile calcification or ossification, and development of ED. The AUA Guidelines Panel conducted a systematic review of the literature using the PubMed(®), EMBASE(®) and Cochrane databases to identify peer-reviewed publications relevant to the diagnosis and treatment of PD. A copy of the 2015 guidelines is attached. The most relevant recommendations are listed below: (I) clinicians should not offer oral therapy with vitamin E, tamoxifen, procarbazine, omega-3 fatty acids, or a combination of vitamin E with L-carnitine. [Moderate recommendation; evidence strength grade B (vitamin E)/B (omega-3 fatty acids)/B (vitamin E propionyl-lcarnitine)/C (tamoxifen)/C (procarbazine)]. (II) Clinicians may administer intralesional collagenase clostridium histolyticum in combination with modeling by the clinician and by the patient for the reduction of penile curvature in patients with stable PD, penile curvature >30. (III) Clinicians should counsel patients with PD prior to beginning treatment with intralesional collagenase regarding potential occurrence of adverse events, including penile ecchymosis, swelling, pain. (IV) Clinicians may offer tunical plication surgery to patients whose rigidity is adequate for coitus (with or without pharmacotherapy and/or vacuum device therapy) to improve penile curvature. (Moderate recommendation; evidence strength grade C). AME Publishing Company 2018-09 /pmc/articles/PMC6186692/ http://dx.doi.org/10.21037/tau.2018.AB002 Text en 2018 Translational Andrology and Urology. All rights reserved.
spellingShingle Plenary Session
Lue, Tom F.
AB002. AUA guideline: update on Peyronie’s disease
title AB002. AUA guideline: update on Peyronie’s disease
title_full AB002. AUA guideline: update on Peyronie’s disease
title_fullStr AB002. AUA guideline: update on Peyronie’s disease
title_full_unstemmed AB002. AUA guideline: update on Peyronie’s disease
title_short AB002. AUA guideline: update on Peyronie’s disease
title_sort ab002. aua guideline: update on peyronie’s disease
topic Plenary Session
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186692/
http://dx.doi.org/10.21037/tau.2018.AB002
work_keys_str_mv AT luetomf ab002auaguidelineupdateonpeyroniesdisease